43,031 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Jennison Associates LLC

Jennison Associates LLC acquired a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 43,031 shares of the company’s stock, valued at approximately $2,485,000. Jennison Associates LLC owned approximately 0.18% of Disc Medicine as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IRON. Adage Capital Partners GP L.L.C. raised its holdings in shares of Disc Medicine by 12.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,308,405 shares of the company’s stock valued at $61,469,000 after acquiring an additional 145,781 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Disc Medicine in the 3rd quarter valued at $6,461,000. Vanguard Group Inc. boosted its position in Disc Medicine by 18.9% during the third quarter. Vanguard Group Inc. now owns 665,452 shares of the company’s stock worth $31,263,000 after acquiring an additional 105,685 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Disc Medicine by 309.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 84,200 shares of the company’s stock worth $3,956,000 after purchasing an additional 63,644 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in Disc Medicine during the third quarter worth $2,966,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director William Richard White sold 2,560 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total transaction of $81,408.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.71% of the company’s stock.

Disc Medicine Stock Up 3.9 %

NASDAQ IRON opened at $27.55 on Friday. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The firm has a 50 day moving average of $50.99 and a two-hundred day moving average of $54.62. The stock has a market capitalization of $665.06 million, a PE ratio of -7.89 and a beta of 0.18.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). On average, equities research analysts expect that Disc Medicine, Inc. will post -4.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IRON has been the subject of a number of recent research reports. BMO Capital Markets cut their target price on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a research note on Tuesday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Disc Medicine in a report on Monday, April 1st. Raymond James reissued an “outperform” rating and set a $40.00 price target (down previously from $75.00) on shares of Disc Medicine in a research report on Monday, April 1st. Stifel Nicolaus upped their target price on shares of Disc Medicine from $71.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Wedbush reissued an “outperform” rating and issued a $43.00 price target (down previously from $84.00) on shares of Disc Medicine in a research report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Disc Medicine currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.29.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.